Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
Central serous choroidal (CSC) retinopathy is a disease of the macula characterized by
exudation of fluid under the retina localized to the posterior pole as well as loss of
vision. The etiology is unknown, but according to the studies this condition is more common
in young males and is associated with type A personality. Clinically, CSC is characterized by
serous retinal detachment and area of leakage of in the subretinal space. The standard of
care for acute CSC is observation for a period of up to 3 months. If there is no complete
resolution of the retinal detachment by 3 months, there is an indication for focal laser
photocoagulation therapy of the area of leakage. This treatment is usually effective in
stopping leakage of fluid under the retina and causing resolution of detachment. However,
laser photocoagulation therapy is not beneficial in the treatment of chronic CSC because
there is not a single easily identifiable point of leakage but rather diffuse disease of RPE
thus rendering laser treatment ineffective.The purpose of this medical research study is to
evaluate Verteporfin therapy as an approach which may benefit patients with CSC, based on
observations in exudative type of AMD patients treated with Photodynamic Therapy using
Verteporfin.